U.S. markets closed

BeiGene, Ltd. (BGNE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
319.61+10.83 (+3.51%)
At close: 4:00PM EDT

319.61 0.00 (0.00%)
After hours: 4:00PM EDT

BeiGene, Ltd.

No.30 Science Park Road
Zhong-Guan-Cun Life Science Park Changping District
Beijing 102206
86 01 0851 48500

Full Time Employees5,400

Key Executives

NameTitlePayExercisedYear Born
Mr. John V. OylerCo-Founder, Exec. Chairman & CEO1.58MN/A1968
Dr. Xiaobin Wu Ph.D.Pres, COO & GM of China1.13MN/A1963
Dr. Xiaodong WangCo-Founder & Non-Exec. Director4MN/A1963
Dr. Heng LiangCFO & Chief Strategy Officer694.61k7.79M1963
Dr. Edna Huang M.D.Chief Medical Officer of Hematology705.49k9.03M1973
Mr. Daniel MallerVP of Fin. & AccountingN/AN/AN/A
Mr. Michael GarveyGlobal Head of Technical OperationsN/AN/A1973
Mr. Craig West CFASr. Director of Investor RelationsN/AN/AN/A
Mr. Scott SamuelsSr. VP & Gen. CounselN/AN/AN/A
Ms. Diana Lee FrancisVP and Global Head of Quality & Regulatory ComplianceN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


BeiGene, Ltd., a commercial-stage biotechnology company, engages in discovering, developing, manufacturing, and commercializing medicines for cancer therapeutics in the People's Republic of China and the United States. Its commercial products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and BAT1706 to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company was incorporated in 2010 and is headquartered in Beijing, the People's Republic of China.

Corporate Governance

BeiGene, Ltd.’s ISS Governance QualityScore as of April 30, 2021 is 6. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.